A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma.

Geoffrey I ShapiroPatricia LoRussoAfshin DowlatiKhanh T DoCaron A JacobsonUlka VaishampayanAmy WeisePaolo F CaimiJoseph Paul EderChristopher A FrenchEmily Labriola-TompkinsFrédéric BoisserieWilliam E PierceallJianguo ZhiSharon PasseMark DeMarioMartin KornackerPhilippe Armand

Published in: British journal of cancer (2020)

NCT01987362.

Keyphrases

diffuse large b cell lymphoma
epstein barr virus
open label
protein protein
amino acid
double blind
binding protein
randomized controlled trial
small molecule